BioXcel Therapeutics BTAI Q1 2026 Earnings EPS Misses Expectations as PreRevenue Biotech Focuses on Pipeline Progress GRCE Q1 2026 Earnings NarrowerThanExpected Loss Highlights Cost Discipline DouYu Q4 2025 Earnings Massive EPS Beat Yet Stock Declines Amid Revenue Uncertainty HUBG Q3 2025 Earnings EPS Misses Estimates by Narrow Margin Stock Edges Higher LULU Q1 2026 Earnings EPS Beats Estimates Amid Modest Stock Uptick XOMAP Q1 2026 Earnings EPS Misses Estimates with Significant Negative Surprise